Adenosine A2A Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Adenosine A2a receptor (A2AR, ADORA2A) is a Gs protein-coupled receptor that stimulates adenylate cyclase activity, increasing intracellular cAMP levels. A2AR is highly enriched in the striatum (caudate nucleus and putamen) where it plays a critical role in modulating motor control, reward processing, and habit formation. This receptor has emerged as a major therapeutic target for Parkinson's disease, with the A2AR antagonist istradefylline (Nourianz) FDA-approved as an adjunct therapy. Beyond PD, A2AR modulators are being investigated for Alzheimer's disease, schizophrenia, depression, and cancer immunotherapy.
A2AR is a typical GPCR with seven transmembrane domains:
| Ligand Type | Examples | Binding Site | Clinical Use |
|---|---|---|---|
| Antagonists | Istradefylline, Caffeine, SCH58261 | Orthosteric site | PD, stroke |
| Agonists | CGS21680, Regadenoson | Orthosteric site | Cardiac stress testing |
| Allosteric modulators | VCP746 | Allosteric site | Investigational |
Key structural elements:
A2AR shows highly region-specific expression:
| Brain Region | Expression Level | Functional Role |
|---|---|---|
| Striatum (Caudate/Putamen) | Very High | Motor control, habit learning |
| Nucleus Accumbens | High | Reward, motivation |
| Olfactory Bulb | High | Olfactory processing |
| Hippocampus | Moderate | Memory, plasticity |
| Cortex | Low-Moderate | Cognitive functions |
| Thalamus | Low | Sensory modulation |
| Cerebellum | Low | Motor coordination |
A2AR activates Gs/olf proteins leading to:
| Pathway Signaling Pathways | Effect | Physiological Consequence |
|---|---|---|
| MAPK/ERK | Activation | Cell proliferation, plasticity |
| PI3K/AKT | Activation | Survival, autophagy |
| NF-κB | Modulation | Inflammation regulation |
| β-arrestin | Recruitment | Desensitization, signaling |
A2AR-D2R interaction is crucial in striatum:
A2AR is the primary therapeutic target in PD:
Emerging evidence for A2AR involvement:
A2AR dysfunction implicated in schizophrenia:
| Condition | Role | Therapeutic Approach |
|---|---|---|
| Depression | Anhedonia, motivation | A2AR antagonists |
| Anxiety | Stress response | A2AR modulation |
| Cancer | Immunosuppression | A2AR antagonists |
| Stroke | Neuroprotection | A2AR antagonists |
| Huntington's Disease | Motor symptoms | Investigation ongoing |
| Drug | Approval | Indication | Mechanism |
|---|---|---|---|
| Istradefylline (Nourianz) | 2019 | Parkinson's disease | A2AR antagonist |
| Compound | Company | Phase | Indication |
|---|---|---|---|
| Tozadenant | Biotie | Phase 3 (withdrawn) | PD |
| Preladenant | Merck | Phase 3 (failed) | PD |
| ST1535 | Sigma-Tau | Phase 2 | PD |
| Vipadenant | Vicore | Phase 2 | PD |
The study of Adenosine A2A Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID:10629201 - A2a adenosine receptor
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID:10816402 - Striatal A2a receptors
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID:15604288 - Parkinson's disease therapy
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID:17585956 - A2a receptor structure
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID:19029120 - Therapeutic potential
[6]: https://pubmed.ncbi.nlm.nih.gov/20139464/ PMID:20139464 - Clinical trials in PD
[7]: https://pubmed.ncbi.nlm.nih.gov/23452928/ PMID:23452928 - A2a-D2a receptor interaction
[8]: https://pubmed.ncbi.nlm.nih.gov/25872154/ PMID:25872154 - Neuroinflammation